中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites

DOI: 10.3969/j.issn.1001-5256.2020.07.015
Research funding:

 

  • Published Date: 2020-07-20
  • Objective To investigate the difference in intestinal flora between hepatitis B liver cirrhosis( HBLC) patients with or without ascites. Methods A total of 57 patients with HBLC who visited Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from October to December 2016 were enrolled,among whom 30 had no ascites( HBLC-WOA group) and 27 had ascites without spontaneous peritonitis( SBP)( HBLC-WA group),and 28 healthy volunteers were enrolled as healthy controls( HC group). Intestinal flora was compared between the two groups of HBLC patients using 16 S rRNA sequencing. The Wilcoxon rank sum test was used for comparison of categorical data between two groups,and the Mann-Whitney U test was used for comparison of continuous data between two groups;the Kruskal-Wallis H test was used for comparison of continuous variables between more than two groups. Multiple hypothesis tests were used for comparison of relative abundance between species and was adjusted by Benjamini and Hochberg false discovery rate( fdr),and Pfdr< 0. 05 was considered statistically significant. The Spearman rank correlation test was used for correlation analysis. An analysis of similarity( ANOSIM) and a non-parametric multivariate analysis of variance( Adonis) were used for comparison between groups under different conditions. Results The abundance of fecal microbiota gradually decreased with the appearance of ascites in HBLC patients( P = 0. 042).There were significant differences between the HBLC-WOA group and the HC group( ANOSIM: R = 0. 159,P = 0. 001; Adonis: R2=0. 067,P = 0. 001) and between the HBLC-WA group and the HC group( ANOSIM: R = 0. 323,P = 0. 001; Adonis: R2= 0. 107,P =0. 001). At the genus level,compared with the HC group,the HBLC-WA group had significant reductions in the abundance of Subdoligranulum and Pseudobutyrivibrio( P < 0. 01 and P < 0. 001) and significant increases in the abundance of Enterobacter,Escherichia,and Veillonella( P < 0. 05,P < 0. 001,and P < 0. 01). Escherichia and Veillonella were positively correlated with Child-Turcotte-Pugh( CTP) score,prothrombin time,and international normalized ratio and were negatively correlated with serum albumin( Alb) level( all P <0. 05). Pseudobutyrivibrio,norank _f _ Lachnospiraceae,unclassified _ f _ Lachnospiraceae,and Blautia were positively correlated with Alb level and were negatively correlated with CTP score and C-reactive protein level( all P < 0. 05). The KEGG pathway analysis showed that with the appearance of ascites,there were gradual increases in the abundance of the pathways associated with transcription-related proteins,alpha-linolenic acid metabolism,Staphylococcus aureus infection,bacterial invasion of epithelial cells,and bile secretion( all Pfdr< 0. 05),as well as a gradual reduction in the abundance of the pathway associated with the biosynthesis of flavonoids( Pfdr< 0. 05). The pathway associated with bacterial invasion of epithelial cells was positively correlated with the abundance of Escherichia( P < 0. 001),and the abundance of Enterobacter was positively correlated with the pathway of bile secretion( P < 0. 001). Conclusion Intestinal flora disturbance is observed in HBLC-WA patients,featuring the reductions in the abundance of Subdoligranulum and Pseudobutyrivibrio belonging to Firmicutes and the increases in the abundance of Enterobacter and Escherichia belonging to Proteobacteria. Enterobacter may be involved in the pathway of bile secretion,and Escherichia may be involved in the pathway associated with bacterial invasion of epithelial cells. It is suggested that regulation of intestinal flora,as well as the prophylactic treatment of SBP,should be considered for HBLC-WA patients without SBP.

     

  • [1]LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.
    [2]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:The major impact of China[J].Hepatology,2014,60(6):2099-2108.
    [3]HENDRIKX T,SCHNABL B.Antimicrobial proteins:Intestinal guards to protect against liver disease[J].J Gastroenterol,2019,54(3):209-217.
    [4]SENDER R,FUCHS S,MILO R.Revised estimates for the number of human and bacteria cells in the body[J].PLo S Biol,2016,14(8):e1002533.
    [5]HARTMANN P,CHEN WC,SCHNABL B.The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease[J].Front Physiol,2012,3:402.
    [6]LIN R,ZHOU L,ZHANG J,et al.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.
    [7]BHAT M,ARENDT BM,BHAT V,et al.Implication of the intestinal microbiome in complications of cirrhosis[J].World J Hepatol,2016,8(27):1128-1136.
    [8]GINS P,QUINTERO E,ARROYO V,et al.Compensated cirrhosis:Natural history and prognostic factors[J].Hepatology,1987,7(1):122-128.
    [9]D'AMICO G,GARCIA-TSAO G,PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:A systematic review of 118studies[J].J Hepatol,2006,44(1):217-231.
    [10]van ERPECUM KJ.Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis[J].Scand J Gastroenterol Suppl,2006,243:79-84.
    [11]GINS P,CRDENAS A,ARROYO V,et al.Management of cirrhosis and ascites[J].N Engl J Med,2004,350(16):1646-1654.
    [12]BENTEN D,WIEST R.Gut microbiome and intestinal barrier failure-the“Achilles heel”in hepatology?[J].J Hepatol,2012,56(6):1221-1223.
    [13]WIEST R,KRAG A,GERBES A.Spontaneous bacterial peritonitis:Recent guidelines and beyond[J].Gut,2012,61(2):297-310.
    [14]WIEST R,GARCIA-TSAO G.Bacterial translocation(BT)in cirrhosis[J].Hepatology,2005,41(3):422-433.
    [15]NOLAN JP.The role of intestinal endotoxin in liver injury:A long and evolving history[J].Hepatology,2010,52(5):1829-1835.
    [16]GILL SR,POP M,DEBOY RT,et al.Metagenomic analysis of the human distal gut microbiome[J].Science,2006,312(5778):1355-1359.
    [17]CHEN Y,YANG F,LU H,et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology,2011,54(2):562-572.
    [18]SANTIAGO A,POZUELO M,POCA M,et al.Alteration of the serum microbiome composition in cirrhotic patients with ascites[J].Sci Rep,2016,6:25001.
    [19]KANG Y,CAI Y.Gut microbiota and hepatitis-B-virus-induced chronic liver disease:Implications for faecal microbiota transplantation therapy[J].J Hosp Infect,2017,96(4):342-348.
    [20] QIN J,LI R,RAES J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464(7285):59-65.
    [21]LU H,WU Z,XU W,et al.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection.Intestinal microbiota of HBV cirrhotic patients[J].Microb Ecol,2011,61(3):693-703.
    [22]TUOMISTO S,PESSI T,COLLIN P,et al.Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics[J].BMC Gastroenterol,2014,14:40.
    [23]BAJAJ JS,BETRAPALLY NS,HYLEMON PB,et al.Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J].Hepatology,2015,62(4):1260-1271.
    [24]QIN N,YANG F,LI A,et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature,2014,513(7516):59-64.
    [25]WEI X,YAN X,ZOU D,et al.Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J].BMC Gastroenterol,2013,13:175.
    [26]FAITH JJ,GURUGE JL,CHARBONNEAU M,et al.The longterm stability of the human gut microbiota[J].Science,2013,341(6141):1237439.
    [27]BAJAJ JS,HEUMAN DM,HYLEMON PB,et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol,2014,60(5):940-947.
    [28]BALMER ML,SLACK E,de GOTTARDI A,et al.The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota[J].Sci Transl Med,2014,6(237):237ra66.
    [29]PONZIANI FR,ZOCCO MA,CERRITO L,et al.Bacterial translocation in patients with liver cirrhosis:Physiology,clinical consequences,and practical implications[J].Expert Rev Gastroenterol Hepatol,2018,12(7):641-656.
    [30]TANG R,WEI Y,LI Y,et al.Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J].Gut,2018,67(3):534-541.
    [31]YANG R,XU Y,DAI Z,et al.The immunologic role of gut microbiota in patients with chronic HBV infection[J].J Immunol Res,2018,2018:2361963.
    [32]TILG H,CANI PD,MAYER EA.Gut microbiome and liver diseases[J].Gut,2016,65(12):2035-2044.
  • Relative Articles

    [1]Liu Li, Jiang YingYi, Liu Jing. Glucose metabolism and insulin secretion in patients with chronic hepatitis B cirrhosis of different Child-Pugh grades and their association with inflammatory response[J]. Journal of Clinical Hepatology, 2020, 36(2): 324-328. doi: 10.3969/j.issn.1001-5256.2020.02.018
    [2]Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013
    [3]He YuLan, Sun Lin, Yu HongWei, Meng QingHua. Expression of glucose transporter 2 in liver tissue in patients with hepatogenous diabetes and its significance[J]. Journal of Clinical Hepatology, 2017, 33(3): 512-515. doi: 10.3969/j.issn.1001-5256.2017.03.023
    [4]Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Clinical features of acute hepatitis B and acute exacerbation of chronic hepatitis B: a comparative study[J]. Journal of Clinical Hepatology, 2016, 32(4): 706-710. doi: 10.3969/j.issn.1001-5256.2016.04.019
    [5]Ruan JianWen, Gao LiJuan, Su RuKai. Clinical features of patients with acute exacerbation of chronic hepatitis B: an analysis of 74 cases[J]. Journal of Clinical Hepatology, 2016, 32(11): 2096-2098. doi: 10.3969/j.issn.1001-5256.2016.11.017
    [6]Xun YunHao, Guo JianChun. Clinical application of traditional Chinese medicine constitution theory in diagnosis and treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 644-648. doi: 10.3969/j.issn.1001-5256.2016.04.006
    [7]Zhang ZeTian, Ji HuiFan, Chen Shuai, Li Xu, Yang WenXuan, Zhang GuoShan, Guo XiaoLin. Clinical cure of chronic hepatitis B: a case report[J]. Journal of Clinical Hepatology, 2016, 32(8): 1578-1579. doi: 10.3969/j.issn.1001-5256.2016.08.030
    [8]Zhang WenJie, Chen QiDan, Wan Yu, Deng Hui. Clinical features of male patients with alcoholic liver cirrhosis or hepatitis B cirrhosis complicated by abnormal glucose metabolism[J]. Journal of Clinical Hepatology, 2016, 32(2): 296-300. doi: 10.3969/j.issn.1001-5256.2016.02.020
    [9]Gao YueQiu. Strategy for traditional Chinese medicine prevention and treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(1): 35-37. doi: 10.3969/j.issn.1001-5256.2015.01.008
    [10]Peng Hong, Yang Jian, Mai RunZhang, Chen HongTao. Relationship between serum adiponectin level and metabolic indices in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(4): 354-356. doi: 10.3969/j.issn.1001-5256.2014.04.016
    [11]Zhang LiHang, Mao JunLing, Ren HaiFeng, Wang ShanJuan, Zhang Hui, Wan Jian, Liu YanLi, Wang YiFei, Lin YongHui. Relationship between glucose metabolism and hepatic encephalopathy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(7): 532-534. doi: 1001-5256 (2013) 07-0532-03
    [12]Hepatobiliary Disease Group, Internal Medicine of Traditional Chinese, China Association of Traditional Chinese Medicine, Expert Consensus of Hepatology, World Federation of Chinese Medicine Societies, Hepatology Group, Chinese Association of the Integration of Traditional and Western Medicine. Guidelines for traditional Chinese medical diagnosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2012, 28(3): 164-168.
    [13]Zhu QiRong. Nosocomial infections and chronic severe hepatitis B: A clinical study of 162 patients[J]. Journal of Clinical Hepatology, 2012, 28(7): 525-527.
    [14]Li ChunXia, Pan HuaiQiang, Li YanJun, Xu GuangHua, Chen YanPing, Feng JiHong, Wei Hua, Ceng QingLei. One case report of occult hepatitis B infection[J]. Journal of Clinical Hepatology, 2012, 28(1): 66-68.
    [15]Yang Song, Cheng Jun. Interpretation of Chinese guideline on prevention and treatment for chronic hepatitis B (2011version) -status quo and prospect of antiviral therapy[J]. Journal of Clinical Hepatology, 2011, 27(8): 794-795+800.
    [16]Qiu YingFeng, Ding YongGang, Li GuangMing. Analysis of therapeutic effect of adefovir dipivoxil in continued treatment of chronic hepatitis B patients with poor early virological response to initial treatment[J]. Journal of Clinical Hepatology, 2011, 27(6): 611-613.
    [17]Huang WeiShen, Yang Li. Predicting scoring system for hepatocellular carcinoma development in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2011, 27(4): 363-364.
    [18]Li Hai, Jia JiDong. Interpretation of the guideline on prevention and treatment for chronic hepatitis B (2010 version) -the goals and indications for chronic hepatitis B treatment[J]. Journal of Clinical Hepatology, 2011, 27(8): 791-793.
    [19]Jin QingLong, Wang ZhongFeng, Yan HongQing, Niu JunQi. The study of the change in creatine kinase in patients with chronic hepatitis B during the antiviral treatment with Telbivudine and Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(2): 143-144+156.
    [20]Li Zhi, Yan HongMei, Xue FaXuan, Wang Tong, Liang Qun, Xu Huan, Li ZhangChun. Short-term clinical effect of telbivudine in the treatment chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(6): 420-421+426.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-04010203040
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.7 %FULLTEXT: 4.7 %META: 89.6 %META: 89.6 %PDF: 5.7 %PDF: 5.7 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.3 %其他: 7.3 %其他: 3.1 %其他: 3.1 %Canada: 0.5 %Canada: 0.5 %College Station: 0.5 %College Station: 0.5 %India: 0.2 %India: 0.2 %Kao-sung: 0.2 %Kao-sung: 0.2 %Malvern: 0.5 %Malvern: 0.5 %Russian Federation: 0.2 %Russian Federation: 0.2 %[]: 2.6 %[]: 2.6 %上海: 2.6 %上海: 2.6 %东京都: 0.2 %东京都: 0.2 %中山: 0.3 %中山: 0.3 %丽水: 0.5 %丽水: 0.5 %休斯顿: 0.2 %休斯顿: 0.2 %加利福尼亚州: 0.2 %加利福尼亚州: 0.2 %北京: 2.8 %北京: 2.8 %匹兹堡: 0.5 %匹兹堡: 0.5 %华城: 0.7 %华城: 0.7 %南京: 0.2 %南京: 0.2 %南宁: 0.2 %南宁: 0.2 %印第安纳波利斯: 0.5 %印第安纳波利斯: 0.5 %台州: 2.1 %台州: 2.1 %合肥: 0.2 %合肥: 0.2 %吉林: 0.2 %吉林: 0.2 %哥伦布: 0.2 %哥伦布: 0.2 %安條克: 0.2 %安條克: 0.2 %密蘇里城: 0.2 %密蘇里城: 0.2 %广州: 0.3 %广州: 0.3 %张家口: 3.0 %张家口: 3.0 %成都: 0.3 %成都: 0.3 %昆明: 0.7 %昆明: 0.7 %杭州: 1.2 %杭州: 1.2 %武汉: 1.0 %武汉: 1.0 %沈阳: 0.3 %沈阳: 0.3 %波士顿: 0.3 %波士顿: 0.3 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.2 %洛阳: 0.2 %济南: 0.2 %济南: 0.2 %深圳: 0.2 %深圳: 0.2 %湖州: 1.2 %湖州: 1.2 %特洛伊: 0.2 %特洛伊: 0.2 %绍兴: 0.2 %绍兴: 0.2 %芒廷维尤: 28.0 %芒廷维尤: 28.0 %芝加哥: 0.5 %芝加哥: 0.5 %苏州: 0.2 %苏州: 0.2 %莫斯科: 1.0 %莫斯科: 1.0 %莱克朗兰比塞特尔: 0.2 %莱克朗兰比塞特尔: 0.2 %蚌埠: 0.3 %蚌埠: 0.3 %衢州: 0.7 %衢州: 0.7 %西宁: 28.3 %西宁: 28.3 %西安: 1.0 %西安: 1.0 %诺沃克: 0.2 %诺沃克: 0.2 %重庆: 0.2 %重庆: 0.2 %长春: 1.2 %长春: 1.2 %长沙: 0.3 %长沙: 0.3 %长治: 0.3 %长治: 0.3 %青岛: 0.2 %青岛: 0.2 %首尔特别: 0.7 %首尔特别: 0.7 %其他其他CanadaCollege StationIndiaKao-sungMalvernRussian Federation[]上海东京都中山丽水休斯顿加利福尼亚州北京匹兹堡华城南京南宁印第安纳波利斯台州合肥吉林哥伦布安條克密蘇里城广州张家口成都昆明杭州武汉沈阳波士顿洛杉矶洛阳济南深圳湖州特洛伊绍兴芒廷维尤芝加哥苏州莫斯科莱克朗兰比塞特尔蚌埠衢州西宁西安诺沃克重庆长春长沙长治青岛首尔特别

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1354) PDF downloads(160) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return